MarketPulse

rare blood disorders

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Over CRISPR: Why Profitable Gene-Editing Beats Pipeline Dreams

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.
VRTXCRSPclinical trialspipeline candidates
The Motley FoolThe Motley Fool··Jonathan Ponciano

BVF's $52M Stake in Disc Medicine Signals Confidence Despite Regulatory Hurdles

BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.
KYMRRVMDRVMDWIRONFDA approvalclinical trial